Acemetacin

Listed in Dosage.

Adult: PO Pain and inflammation associated w/ musculoskeletal and joint disorders; Post-op pain Initial: 120 mg/day in divided doses, may increase to 180 mg.

Should be taken with food. Take w/ or immediately after meals.

Hypersensitivity to acemetacin or indometacin and other NSAIDS. Active or history of peptic ulcer/haemorrhage, history of GI bleeding or perforation related to previous NSAID therapy, blood formation disorder of unclear etiology, nasal polyps (associated w/ angioneurotic oedema), severe heart failure. Severe renal and hepatic impairment. Pregnancy (3rd trimester).

Patient w/ history of GI toxicity, resp disorder (e.g. asthma, hay fever, swollen nasal mucosae, chronic resp disease), uncontrolled HTN, CHF, ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, hyperlipidaemia, DM, ulcerative colitis, Crohn's disease, SLE, mixed connective tissue disorders, chickenpox, herpes zoster, parkinsonism. Hepatic and renal impairment. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, drowsiness, fatigue, and visual disturbances, if affected, do not drive or operate machinery. Monitoring Parameters Monitor haemogram and blood coagulation, liver and kidney function.

Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, gastritis; asthma, bronchospasm, dyspnoea; pruritus, urticaria, purpura, angioedema; HTN, oedema, cardiac failure; agitation; headache, dizziness, malaise, drowsiness, increased hepatic enzyme; alopecia; retinal pigment degeneration, corneal opacity. Rarely, pancreatitis, exfoliative and bullous dermatoses (e.g. epidermal necrolysis, erythema multiforme); necrotising fasciitis; hyperglycaemia, glucosuria; hyperkalaemia; irritability, confusion.
Potentially Fatal: GI bleeding, ulceration or perforation. Rarely, severe hypersensitivity reactions, including angioneurotic oedema, resp distress which may lead to asthma attack, tachycardia or decreased BP leading to shock.

May increase risk of AR w/ other NSAIDs. Increased GI ulceration/bleeding w/ corticosteroids, anti-platelet agents, and SSRIs. Reduced resorption rate w/ antacids. Reduced elimination w/ probenecid, sulfinpyrazone. May reduce the effect of diuretics and antihypertensive agents. May reduce elimination of phenytoin, lithium, methotrexate. Increased risk of nephrotoxicity w/ ciclosporin and diuretics.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

M01AB11 - acemetacin ; Belongs to the class of acetic acid derivatives and related substances of non-steroidal antiinflammatory and antirheumatic products.